- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ionis Pharmaceuticals Inc (IONS)Ionis Pharmaceuticals Inc stock price live, this page displays NASDAQ IONS stock exchange data. View the IONS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ionis Pharmaceuticals Inc real time stock price chart below.
What Is the Ionis Pharmaceuticals Inc Stock Price Today?
The Ionis Pharmaceuticals Inc stock price today is 38.58.
What Is the Stock Symbol for Ionis Pharmaceuticals Inc?
The stock symbol for Ionis Pharmaceuticals Inc is "IONS."
What Stock Exchange Does Ionis Pharmaceuticals Inc Trade On?
Ionis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Ionis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Ionis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IONS quote. (ISIN: US4622221004)
What Is the Ionis Pharmaceuticals Inc Stock Price Today?
The Ionis Pharmaceuticals Inc stock price today is 38.58.
What Is the Stock Symbol for Ionis Pharmaceuticals Inc?
The stock symbol for Ionis Pharmaceuticals Inc is "IONS."
What Stock Exchange Does Ionis Pharmaceuticals Inc Trade On?
Ionis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Ionis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Ionis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IONS quote. (ISIN: US4622221004)
Currency in USD
38.58
+0.47(+1.23%)
Closed
After Hours
39.21+0.63(+1.63%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.52
40.10
52 wk Range
33.33
54.44
IONS Scorecard
Full Analysis
Significant return over the last week
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.5240.10
52 wk Range
33.3354.44
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
IONS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
61.20
Upside
+58.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Ionis to present at upcoming investor conferences
- Investing.com
- Isis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Isis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ionis to present at upcoming investor conferences
- Investing.com
Ionis Pharmaceuticals Inc Company Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Ionis Pharmaceuticals Inc SWOT Analysis
Pipeline Potential | Explore Ionis' late-stage candidates, including eplontersen for ATTR and donidalorsen for HAE, poised to reshape treatment paradigms in rare diseases |
Financial Trajectory | Analysts project Ionis reaching EBIT trough in 2024, with multiple product launches driving revenue growth and potential cash-flow positivity by 2027 |
Market Opportunities | Delve into Ionis' target markets, including the vast ATTR-CM space with up to 500,000 US patients, and the underappreciated potential in SHTG |
Analyst Outlook | Average price target of $60, ranging from $45 to $70, reflects optimism about Ionis' robust pipeline and upcoming catalysts amid execution risks |
IONS Full Pro Research
Institutional-Grade Stock Analysis
Understand how IONS earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Ionis Pharmaceuticals Inc Earnings Call Summary for Q1/2024
- Positive Phase 3 data for olezarsen and donidalorsen; regulatory submissions planned in US and Europe
- 2023 non-GAAP operating loss of $247M; revenues of $788M exceeded guidance
- 2024 revenue projection over $575M, driven by WAINUA launch and R&D partnerships
- Expanded Phase 3 pipeline with 9 medicines in Phase 2, targeting multibillion-dollar revenue opportunities
- Year-end cash balance projected at $1.7B despite increased expenses; mid-single-digit increase in operating costs expected
Last Updated: 2024-02-22, 09:41 a/m
Read Full TranscriptCompare IONS to Peers and Sector
Metrics to compare | IONS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIONSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.0x | −7.9x | −0.6x | |
PEG Ratio | −1.18 | −0.22 | 0.00 | |
Price/Book | 9.2x | 2.6x | 2.6x | |
Price / LTM Sales | 7.6x | 3.5x | 3.2x | |
Upside (Analyst Target) | 62.7% | 34.8% | 46.2% | |
Fair Value Upside | Unlock | 8.5% | 7.0% | Unlock |
Analysts' Recommendations
17 Buy
7 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 61.20
(+58.63% Upside)
People Also Watch
FAQ
What Is the Ionis Pharma (IONS) Stock Price Today?
The Ionis Pharma stock price today is 38.58
What Stock Exchange Does Ionis Pharma Trade On?
Ionis Pharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Ionis Pharma?
The stock symbol for Ionis Pharma is "IONS."
What Is the Ionis Pharma Market Cap?
As of today, Ionis Pharma market cap is 6.12B.
What is Ionis Pharma Earnings Per Share?
The Ionis Pharma EPS is -2.46.
What Is the Next Ionis Pharma Earnings Date?
Ionis Pharma will release its next earnings report on Feb 19, 2025.
From a Technical Analysis Perspective, Is IONS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.